Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.

PubWeight™: 0.99‹?› | Rank: Top 15%

🔗 View Article (PMID 16598499)

Published in Virchows Arch on April 06, 2006

Authors

Heike Immervoll1, Dag Hoem, Kalaiarasy Kugarajh, Solrun J Steine, Anders Molven

Author Affiliations

1: Section for Pathology, The Gade Institute, University of Bergen, Haukeland University Hospital, Bergen N-5021, Norway.

Associated clinical trials:

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | NCT03717298

Articles citing this

Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68

Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer (2008) 1.82

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol (2012) 1.08

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer (2012) 1.07

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics (2009) 0.98

Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res (2010) 0.94

Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer (2010) 0.93

Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. J Gastrointest Oncol (2013) 0.93

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer (2011) 0.91

Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid. Diabetes (2013) 0.90

Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. Mod Pathol (2013) 0.89

Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem (2011) 0.89

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One (2013) 0.88

Epidermal growth factor receptor in pancreatic cancer. Cancers (Basel) (2011) 0.87

Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One (2012) 0.81

Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. PLoS One (2010) 0.77

Articles cited by this

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46

Pancreatic cancer. Lancet (2004) 11.63

Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36

Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60

Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54

Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg (2004) 3.90

K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56

Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17

BRAF mutations in papillary carcinomas of the thyroid. Oncogene (2003) 2.94

Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54

Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44

Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol (2004) 2.27

BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res (2003) 2.27

Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg (2003) 2.26

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07

Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia (2005) 2.03

Somatic alterations in the human cancer genome. Cancer Cell (2004) 1.97

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68

BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol (2005) 1.66

Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol (2004) 1.46

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas (2004) 1.43

Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42

The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer (1999) 1.29

K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer (2000) 1.27

Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res (2001) 1.20

Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer (2004) 1.18

Defective DNA mismatch repair in long-term (> or =3 years) survivors with pancreatic cancer. Pancreatology (2005) 1.16

Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol (2004) 1.13

Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene (2004) 1.02

Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch (2004) 1.00

BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett (2003) 0.97

Familial pancreatic cancer. Br J Surg (2003) 0.96

Inherited predisposition to cancer: a historical overview. Am J Med Genet C Semin Med Genet (2004) 0.92

Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol (2004) 0.90

Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol (2004) 0.84

Tracing origin of serrated adenomas with BRAF and KRAS mutations. Virchows Arch (2005) 0.81

A two-step enriched-nested PCR technique enhances sensitivity for detection of codon 12 K-ras mutations in pancreatic adenocarcinoma. Pancreas (1997) 0.79

Comparison of K-ras point mutations at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. J Surg Oncol (2000) 0.78

Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival. Eur J Histochem (1998) 0.76

Articles by these authors

CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer (2008) 3.46

Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29

Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet (2005) 2.22

Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes (2004) 2.10

Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res (2010) 2.09

Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc Natl Acad Sci U S A (2009) 1.93

Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91

Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer (2008) 1.82

FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies. Diabetes (2011) 1.75

BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol (2005) 1.66

Distal phalangeal creases--a distinctive dysmorphic feature in disorders of the RAS signalling pathway? Eur J Med Genet (2007) 1.45

Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol (2007) 1.41

Disruption of a long distance regulatory region upstream of SOX9 in isolated disorders of sex development. J Med Genet (2011) 1.34

Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer (2006) 1.32

From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Diabetes (2006) 1.20

A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17

Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes (2003) 1.15

Pain management in chronic pancreatitis. Eur J Gastroenterol Hepatol (2002) 1.12

Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-ester lipase. Diabetes (2007) 1.09

Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate that variants in the hepatocyte nuclear factor 4 alpha (HNF4A) P2 region are associated with type 2 diabetes in Scandinavians. Diabetes (2007) 1.05

SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet (2013) 1.05

Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol (2008) 1.05

Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04

De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet (2007) 1.02

A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer (2005) 1.01

Exome sequencing and genetic testing for MODY. PLoS One (2012) 1.00

Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study. Med Phys (2013) 1.00

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res (2008) 0.99

Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease. J Biol Chem (2011) 0.99

Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway. J Clin Endocrinol Metab (2003) 0.98

Pancreatic function in carboxyl-ester lipase knockout mice. Pancreatology (2010) 0.94

Mutations in the VNTR of the carboxyl-ester lipase gene (CEL) are a rare cause of monogenic diabetes. Hum Genet (2009) 0.93

A hepatocyte nuclear factor-4 alpha gene (HNF4A) P2 promoter haplotype linked with late-onset diabetes: studies of HNF4A variants in the Norwegian MODY registry. Diabetes (2006) 0.91

Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid. Diabetes (2013) 0.90

Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res (2010) 0.90

The number of tandem repeats in the carboxyl-ester lipase (CEL) gene as a risk factor in alcoholic and idiopathic chronic pancreatitis. Pancreatology (2012) 0.89

Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int (2008) 0.89

Familial occurrence of neonatal diabetes with duplications in chromosome 6q24: treatment with sulfonylurea and 40-yr follow-up. Pediatr Diabetes (2011) 0.89

Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem (2011) 0.89

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One (2012) 0.88

Reduced pancreatic volume in hepatocyte nuclear factor 1A-maturity-onset diabetes of the young. J Clin Endocrinol Metab (2008) 0.88

Detection of clonality in follicular lymphoma using formalin-fixed, paraffin-embedded tissue samples and BIOMED-2 immunoglobulin primers. J Clin Pathol (2010) 0.88

Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry. Pediatr Diabetes (2008) 0.86

Influence of laparoscopic cholecystectomy on the prevalence of operations for gallstones in Norway. Eur J Surg (2002) 0.85

HPV subtypes in cervical cancer biopsies between 1930 and 2004: detection using general primer pair PCR and sequencing. Virchows Arch (2006) 0.85

Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer (2008) 0.85

U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med (2014) 0.85

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. Int J Cancer (2014) 0.84

Evaluation of four novel genetic variants affecting hemoglobin A1c levels in a population-based type 2 diabetes cohort (the HUNT2 study). BMC Med Genet (2011) 0.84

Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Res (2013) 0.84

Quantification of pancreatic function using a clinically feasible short endoscopic secretin test. Pancreas (2013) 0.83

Pancreatic exocrine dysfunction in maturity-onset diabetes of the young type 3. Diabetes Care (2007) 0.83

Functional dissection of the HNF-1alpha transcription factor: a study on nuclear localization and transcriptional activation. DNA Cell Biol (2005) 0.83

MC1R, ASIP, TYR, and TYRP1 gene variants in a population-based series of multiple primary melanomas. Genes Chromosomes Cancer (2012) 0.83

PI3-kinase mutation linked to insulin and growth factor resistance in vivo. J Clin Invest (2016) 0.82

Polygenic risk variants for type 2 diabetes susceptibility modify age at diagnosis in monogenic HNF1A diabetes. Diabetes (2009) 0.82

Severe pancreatic dysfunction but compensated nutritional status in monogenic pancreatic disease caused by carboxyl-ester lipase mutations. Pancreas (2013) 0.81

Absence of diabetes and pancreatic exocrine dysfunction in a transgenic model of carboxyl-ester lipase-MODY (maturity-onset diabetes of the young). PLoS One (2013) 0.81

G protein-coupled receptor agonist-stimulated expression of ATF3/LRF-1 and c-myc and comitogenic effects in hepatocytes do not require EGF receptor transactivation. J Cell Physiol (2004) 0.81

DNA hypomethylation, transient neonatal diabetes, and prune belly sequence in one of two identical twins. Eur J Pediatr (2009) 0.80

HNF1B mutation in a Turkish child with renal and exocrine pancreas insufficiency, diabetes and liver disease. Pediatr Diabetes (2011) 0.79

Assessment of exocrine pancreatic function by secretin-stimulated magnetic resonance cholangiopancreaticography and diffusion-weighted imaging in healthy controls. J Magn Reson Imaging (2013) 0.79

Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies. BMC Endocr Disord (2010) 0.79

Improved diagnostic segregation of mantle cell lymphoma by determination of cyclin D1/D3 expression ratio in formalin-fixed tissue. Diagn Mol Pathol (2009) 0.78

GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation. Biochim Biophys Acta (2012) 0.78

Neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to CEL mutations. Diabetes Care (2008) 0.78

The role of pancreatic imaging in monogenic diabetes mellitus. Nat Rev Endocrinol (2011) 0.78

Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation. Melanoma Res (2013) 0.78

Glycogenin-2 is dispensable for liver glycogen synthesis and glucagon-stimulated glucose release. J Clin Endocrinol Metab (2015) 0.78

Is pharmacogenetic CYP2D6 testing useful? Tidsskr Nor Laegeforen (2010) 0.78

Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma Res (2009) 0.77

Vascular proliferation is associated with survival in pancreatic ductal adenocarcinoma. APMIS (2013) 0.77

De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. BMJ Case Rep (2009) 0.76

Frequency of somatic BRAF mutations in melanocytic lesions from patients in a CDK4 melanoma family. Pigment Cell Melanoma Res (2013) 0.76

[Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway]. Tidsskr Nor Laegeforen (2009) 0.76

Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (2003) 0.76

pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda. BMC Clin Pathol (2009) 0.76

[Molecular diagnostics in diabetes mellitus]. Tidsskr Nor Laegeforen (2005) 0.75

[Progress in diabetes genetics]. Tidsskr Nor Laegeforen (2010) 0.75

Internal abdominal hernia. Tidsskr Nor Laegeforen (2017) 0.75

[Precursors to pancreatic cancer]. Tidsskr Nor Laegeforen (2006) 0.75

[Tailored medicine or narcissomics?]. Tidsskr Nor Laegeforen (2012) 0.75

[Pathology archives--new perspectives on stored tissue material]. Tidsskr Nor Laegeforen (2003) 0.75

Frequencies of KIT and GNAQ mutations in acral melanoma. J Cutan Pathol (2014) 0.75

Diabetes genetics. A seventh sense for the successful sequel of 'come together'. "The genotypes and phenotypes of diabetes". Bergen, Norway. April 22-26, 2009. 2nd meeting of 'EASD Study Group on Genetics of Diabetes' and 44th annual meeting of the 'Scandinavian Society for the Study of Diabetes'. JOP (2009) 0.75